0000000000469306

AUTHOR

G Bronte

showing 6 related works from this author

The impact of the patient's Adjustment to breast cancer of the burden and distress of the caregiver.

2009

breast cancercaregiver
researchProduct

Early stage nasal vestibule tumors: safety and efficacy of HDR brachyterapy in elderly patients

2009

nasal vestibule tumorbrachyterapy
researchProduct

Comparison between palonosetron(P) and aprepitant (A) versus palonosetron alone for antiemetic prophylaxis in advanced soft tissue sarcoma (STS)patie…

2009

sotf tissue sarcoma palonosetron aprepitant prophylaxis
researchProduct

Second-line treatment in exon 11-mutated GIST patients: Imatinib dose escalation or sunitinib? Retrospective analysis of a multi-institutional experi…

2014

10515 Background: Data from metastatic GIST patients harbouring exon 11 mutation who received a second line treatment with sunitinib or imatinib dose escalation were retrospectively analysed to compare survival. Methods: 123 exon 11 mutated advanced GIST patients were included. All patients progressed on imatinib 400 mg/die and received, on discretion of physician, a second line treatment with either imatinib (800 mg/die) or sunitinib (50 mg/die 4 weeks on/2 weeks of or 37.5 mg/day continuous daily dose). The type of exon 11 mutation was recorded (deletion versus others) and correlated with survival and response according to RECIST or CHOI criteria Results: 79 patients (64%) received a seco…

OncologyCancer Researchmedicine.medical_specialtySecond line treatmentGiSTSunitinibbusiness.industryImatinibMetastatic gistSurgeryExonOncologyInternal medicineDose escalationmedicineRetrospective analysisbusinessneoplasmsmedicine.drugJournal of Clinical Oncology
researchProduct

Trattamento con lanreotide di un caso di gastrinoma già trattao con 177Lu-DOTATATE

2009

gastrinoma MEN-1Settore MED/13 - Endocrinologia
researchProduct

Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA)

2011

Background: A recent pooled analysis of randomized trials indicated significant improvement in overall survival from cisplatin-based adjuvant chemotherapy for non-small cell lung cancer (NSCLC), depending on disease stage (only in stages II and III) and PS (≤1). Post-operative radiotherapy (RT) is optional for pN2 tumours. Patients and methods: To evaluate opinions and daily clinical practice of Italian Oncologists about adjuvant treatment of NSCLC, a 46-item questionnaire was delivered via e-mail. Results: Seventy-eight physicians from 68 Centers (out of 98 contacted) returned their questionnaire. Seventy-four, 86, 94, and 78% of them give the indication for adjuvant chemotherapy for stage…

OncologyCancer ResearchLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentDiseasechemotherapyDeoxycytidinelaw.inventionCarboplatinRandomized controlled trialNon-small cell lung cancerlawCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsPostoperative radiotherapyStage (cooking)Non-Small-Cell LungSurveyVinorelbineOncologyChemotherapy AdjuvantAdjuvantmedicine.drugHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyPaclitaxelnon-small cell lung cancer; adjuvant; Survey; chemotherapyVinblastineadjuvantInternal medicinemedicineHumansLung cancerNeoplasm StagingCisplatinAntineoplastic Combined Chemotherapy ProtocolRadiotherapybusiness.industryCarcinomamedicine.diseaseGemcitabineSurgeryAdjuvant chemotherapyRadiation therapyLung NeoplasmRegimenHealth Care SurveysAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; SurveyAdjuvant chemotherapy; Non-small cell lung cancer; Postoperative radiotherapy; Survey; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma Non-Small-Cell Lung; Chemotherapy Adjuvant; Cisplatin; Deoxycytidine; Humans; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Radiotherapy Adjuvant; Vinblastine; Vinorelbine; Health Care Surveys; Oncology; Pulmonary and Respiratory Medicine; Cancer ResearchRadiotherapy AdjuvantCisplatinbusiness
researchProduct